Multicentre Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery

Not Applicable

Recruiting

• Conditions: Mitral Regurgitation

• Registration Number: NCT03271762
• Lead Sponsor: Nantes University Hospital

Brief Summary

The objective of the study is to demonstrate the non-inferiority for clinical efficacy of an endovascular treatment strategy with the MitraClip® in comparison with a surgical treatment strategy in patients with severe primary mitral regurgitation judged eligible for anatomical repair with the MitraClip® or mitral valve surgery with high surgical risk.

This trial is a French and Monegasque, multicenter and randomized trial. Patients enrolled will be clinically followed for 2 years ( clinical visit at 1 month, at 6 months and 12 months, phone call at 18 months and clincial visit at 24 months).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-08-25
• Study First Submitted QC: 2017-08-31
• Study First Posted: 2017-09-05
• Study Start: 2018-03-02
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-24
• Last Update Posted: 2025-01-27
• Primary Completion: 2027-03
• Study Completion: 2028-05

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 330

Inclusion Criteria

Primary Mitral Regurgitation grade 3+ or 4+

• Patients in class II to IV NYHA
• Mitral valve anatomy appropriate to MitraClip® therapy and mitral valve surgery
• Adult patients judged eligible for mitral valve surgery by the local heart team but at high surgical risk defined as: age ≥ 75 years and STS score ≥ 6 % or one frailty index or one major organ system compromise or one possible procedure-specific impediment (using MVARC definitions) ; or age < 75 years and STS score > 8 % or at least one other high-risk criterion following the MVARC definitions; or age > 80 years and judged at high risk for surgery by the local heart team
• Isolated Mitral valve pathology
• If revascularization procedures are required, they must be performed more than 30 days from intervention (D0)
• Patients affiliate to social security

Non-inclusion Criteria:

• Life expectancy < 1 year due to non-cardiac conditions
• Secondary Mitral regurgitation
• Evolving endocarditis or active endocarditis or inflammatory disease in the last 3 months
• Patient who cannot tolerate procedural anticoagulation or post procedural antiplatelet regimen
• Rheumatic mitral valve disease
• Evidence of intracardiac, inferior vena cava or femoral venous thrombus
• Valve anatomy not compatible with MitraClip® implantation (cf. colum 3 table 3 page 57)
• Stroke or transient ischaemic event within 30 days before D0
• Modified Rankin Scale ≥4 disability (appendix 9)
• TAVR within 30 days before D0-Untreated, clinically significant coronary artery disease requiring revascularization
• Any percutaneous cardiovascular intervention within 30 days before D0 including ATC
• Cardiovascular surgery, or carotid surgery within 30 days before D0
• Any prior mitral valve surgery or transcatheter mitral valve procedure
• Need for any concomitant cardiac surgery including treatment of severe secondary tricuspid regurgitation in accordance with class I recommendation in 2017 ESC guidelines. Surgical treatment of mild or moderate secondary tricuspid regurgitation (Class IIa and IIb recommendations) can still be performed in the protocol according to the local heart team decison
• NYHA functional class I
• LVEF < 30%
• Primary MR grade 1 to 2
• Subjects in whom transesophageal echocardiography or transseptal catheterization are contraindicated or high-risk
• Any condition preventing the patient from completing all protocol procedures (including compliance with guidelines directed medical therapy) and follow-up visits
• Patient unable or unwilling to provide written, informed consent before study enrolment
• Pregnant or nursing women
• Vulnerable people: persons deprived of liberty; under trusteeship or under curatorship
• Participation in another trial that would interfere with this trial

Exclusion criteria

• Not eligible for a MitraClip® intervention after Core Lab evaluation
• Before randomization (D-21) the patient no longer fulfills eligibility criteria (inclusion criteria and non-inclusion criteria)

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
All-cause mortality, unplanned hospitalizations for heart failure and mitral valve reintervention	12 months	comparison between arms of: * number and reason of death; * number and reason unplanned rehospitalisation for cardiovascular reasons,; * number of mitral valve reintervention

Secondary Outcome Measures

Name	Time	Method
occurrence of a major adverse event	30 days	all-cause death, need for non-elective cardiovascular or thoracic surgery, device or procedure-related adverse events, major bleeding complications or serious bleeding, major access site vascular complications, major cardiac structural complications, pulmonary complications (device or procedure-related), stroke and other cerebrovascular events, myocardial infarction, acute kidney injury or progression of chronic kidney disease, arrhythmias and conduction system disturbances, unplanned mitral valve surgery due to device/procedure failure or malfunction, requirement for valve replacement after valve repair failure, unplanned cardiac surgery for any cause

Trial Locations

Locations (34)

Chu Angers; 🇫🇷 Angers, France

Ch Annecy; 🇫🇷 Annecy, France

Clinique Saint Augustin; 🇫🇷 Bordeaux, France

Chu Bordeaux; 🇫🇷 Bordeaux, France

Chru Brest; 🇫🇷 Brest, France

Hopital Henri Mondor Aphp; 🇫🇷 Créteil, France

Chu Grenoble; 🇫🇷 Grenoble, France

Centre Chirurgical Marie Lannelongue; 🇫🇷 Le Plessis-Robinson, France

Chru Lille; 🇫🇷 Lille, France

Hopital Prive Le Bois Lille; 🇫🇷 Lille, France

Scroll for more (24 remaining)